Urology

With AI decision support, basic readers achieved efficiency scores comparable to expert radiologists, suggesting that AI may help standardise prostate cancer diagnosis across different levels of clinical expertise.

EAU 2026 data show prostate cancer screening has minimal impact on men’s quality of life and health anxiety, helping fill a key evidence gap for screening policy.

Researchers compared prostate and breast cancer screening outcomes in Germany in a meta-analysis presented at the Annual Congress of the European Association of Urology 2026.

A new AI model has outperformed traditional methods of bladder cancer classification, yielding a 95.5% accuracy.

First-line treatments for erectile dysfunction are under-prescribed in patients with prostate cancer, despite favourable clinical outcomes.

SBRT was linked to lower biochemical failure and fewer acute urinary adverse events than HDR brachytherapy in intermediate-risk prostate cancer.

Randomised data show leuprolide is linked to greater 12-month coronary plaque progression than relugolix in men receiving ADT for prostate cancer.

Higher levels of leisure-time physical activity after cancer diagnosis were associated with lower cancer mortality in survivors of several tumour types.